We hypothesized that left ventricular (LV) remodeling and matrix loss in volume overload (VO) are mediated by bradykinin (BK) and exacerbated by chronic angiotensin-converting enzyme (ACE) inhibition.
When subjected to a volume overload, the mammalian left ventricular (LV) chamber dilates and remodels in an eccentric manner. It is generally believed that eccentric remodeling occurs by cardiomyocyte elongation and hypertrophy that serves to normalize left ventricular end-diastolic dimension (LVEDD) to wall thickness ratio (1) . Eccentric hypertrophy therefore accommodates the increased preload because end-systolic stress is normal in a compensated volume overload (1, 2) . During the compensated phase of volume overload, forward cardiac output is maintained by a greater-than-normal fractional shortening and stroke volume (2) . In fact, normal or slightly reduced fractional short-
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ening and/or an increase in the LVEDD/wall thickness is associated with a poor outcome in patients with volume overload caused by mitral or aortic valvular regurgitation (2) . Cardiomyocyte elongation and dysfunction are accepted as crucial events during the LV remodeling and decompensation response to volume overload (1) .
Angiotensin-converting enzyme (ACE) inhibitors are widely used to treat heart failure; however, there is emerging evidence showing that ACE inhibitors do not effectively attenuate eccentric remodeling during pure volume overload.
In addition to converting angiotensin I to angiotensin II, ACE binds and cleaves bradykinin (BK) to inactive fragments with an affinity several-fold greater than that for angiotensin I (3). We previously showed an increase in LV interstitial fluid BK during the volume overload of aortocaval fistula (ACF) that is further increased by ACE inhibition (4) . Bradykinin has been shown to decrease collagen production and increase matrix metalloproteinase (MMP) expression in cultured fibroblasts (5) (6) (7) . We hypothesized that the antifibrotic response in acute volume overload, leading to adverse LV remodeling and dysfunction, independent of cardiomyocyte remodeling, is directly mediated by BK. Here we show that the critical early event in LV remodeling and dysfunction is BK-mediated dissolution of the collagen matrix, and not cardiomyocyte elongation. Additionally, chronic ACE inhibition does not attenuate LV remodeling or improve systolic function during volume overload, explaining why ACE inhibitors, which increase antifibrotic BK, are ineffective in the treatment of volume overload.
Methods

Animal preparation.
Abdominal ACF was performed in male Sprague-Dawley rats (200 to 250 g) as previously described (4) . Age-matched sham-and ACF-operated rats were generated for echocardiographic and hemodynamic study at 12 h; 2 and 5 days; and 4, 8, and 15 weeks, after which time they were killed and tissues were collected for morphometry, immunohistochemistry, and protein analysis (n values given in Table 1 ). A separate group of rats was killed at similar time points for isolated myocyte studies (n values given in Table 2 ). In a third group of animals, the BK receptor type 2 (BK 2 R) antagonist Hoe 140 (0.5 mg/kg/day, subcutaneous, Sigma/RBI, Natick, Massachusetts) was started after ACF or sham surgery, and animals were killed at 2 days (n values given in Table 3 ). A subset of rats (n ϭ 8) was treated with angiotensin II (1 g/kg/min, osmotic mini-pump, Bachem Bioscience Inc., King of Prussia, Pennsylvania) for 2 days after ACF to generate a blood pressure increase similar to that with ACF ϩ Hoe 140. In a final group, the ACE inhibitor was started in the drinking water (ramipril at 10 mg/kg/day, Hoechst, Frankfurt, Germany) after induction of ACF or sham, 
Heart weight/body weight* (g/g ϫ 10
Values are mean Ϯ SEM. *Based on variance component analysis. †p Ͻ 0.008 (ϭ 0.05/6) versus SHM. ‡p Ͻ 0.008 versus ACF. LVED ϭ left ventricular end-diastolic; LVEDD ϭ left ventricular end-diastolic dimension; LVEDP ϭ left ventricular end-diastolic pressure; LVES ϭ left ventricular end-systolic; LVESD ϭ left ventricular end-systolic dimension; LVESP ϭ left ventricular end-systolic pressure; other abbreviations as in Table 1 .
Ryan et al. February 20, 2007:811-21 Left Ventricular Remodeling in Volume Overload sion chamber with internal stimulating platinum electrodes (Warner Instruments, Hamden, Connecticut) attached to a Grass stimulator, and imaged using an inverted microscope (Olympus America Inc, Melville, New York) and CCD camera (Philips, Andover, Massachusetts). A rod-shaped cell without blebbing or spontaneous contractions was chosen for imaging. The chamber was perfused with Tyrode basic salt solution and paced (3-ms duration) for 2 min at a starting frequency of 0.5 Hz. The stimulating frequency was stepwise increased from 0.5 to 3 Hz. The contractility of each cell was recorded with a video edge detection system (Crescent Electronics, Sandy, Utah) and analyzed using Digi-Med System Integrator Model 200/1 and Cell Data Analysis software program (MicroMed Technology, Inc., Houston, Texas). At each frequency, data were analyzed after 1 min of pacing. MMP analysis. Left ventricular tissue was homogenized in lysis buffer (0.2% Triton X-100, 10 g/ml aprotinin, 10 g/ml leupeptin, 0.5 mM PMSF, 500 M Na 3 VO 4 ) and centrifuged at 14,000 rpm for 10 min at 4°C. Protein concentrations were assessed with a bicinchonic acid assay. Western blot analysis was performed with monoclonal anti-rat MMP-13, monoclonal anti-rat tissue inhibitor of MMP-1 (TIMP-1), and rabbit polyclonal anti-rat TIMP-4 (all antibodies Chemicon, Temecula, California). Membranes were washed and treated with horseradish peroxidase-conjugated secondary antibodies (goat anti-mouse or anti-rabbit immunoglobulin G). Immunoreactive bands were visualized using enhanced chemiluminescence reagents exposed to Hyperfilm at the linear range of film density. Films were scanned, and densitometric analysis was performed with National Institutes of Health image software. Statistical analyses. All statistical analyses were done using SAS software (SAS Institute Inc., Cary, North Carolina). Generalized linear models (two-factor with interaction and one-factor) were used to analyze all variables. We used the Kolmogorov-Smirnov test and the Levene test on the residuals to check normality and constancy of variance, respectively. If all p values for testing these assumptions were Ͼ0.05, we considered the model a good fit. Otherwise, we did a transformation (natural logarithm or ranks) and then chose the appropriate transformation that would resolve the assumption(s) violated. Problems of non-normality and/or nonconstant variance of the error terms were observed in a majority of the variables. If transformations worked, p values for these goodnessof-fit tests were all Ͼ0.10. Transformations applied to the variables are indicated in the tables and figures. In a few variables, neither log nor rank transformation remedied the goodness-of-fit problem observed. In these cases, we used the Kruskal-Wallis test for 1-factor designs and variance component analyses (via SAS PROC MIXED) to accommodate the unequal variances across the factor combinations for 2-factor designs. All tests were performed using a 5% significance level. The Bonferroni method was used in the pair-wise comparisons for each variable to ensure an overall 5% significance level. Appropriate decision rules based on the Bonferroni adjustment are indicated in the tables and figures.
Results
LV remodeling in ACF.
Twelve hours after the induction of volume overload, LVEDD had increased (p Ͻ 0.05) by 20%, whereas LVEDD/wall thickness was increased by 30% at 2 days after ACF (Figs. 1A and 1B) . There was no increase in cardiomyocyte length at either time (Fig. 1C) . Both LVEDD and LVEDD/wall thickness were increased by 40% at 4 to 15 weeks after ACF (Figs. 1A and 1B) . Mean LV wall thickness decreased (p Ͻ 0.05) at 15 weeks after ACF (Fig. 1D) . Cardiomyocyte length increased by 9% and 18% above shams only at the 8-and 15-week post-ACF time points, respectively (Fig.  1C) , whereas LV weight, which had increased by 40% at 4 weeks after ACF, did not increase further after this point (Fig. 1E) .
Acutely, there was a 75% decrease in collagen volume percent 12 h after ACF that persisted at day 2 (Figs. 2A to 2E). Collagen volume percent returned to sham values by 5 days after ACF (Fig. 2D) ; however, the average diameter of collagen fibers at 5 days was increased compared with sham (Fig. 2F) . Chronically, collagen volume percent was decreased 30% in ACF rats at 4, 8, and 15 weeks (data not shown). Indexes of systolic function in ACF. Mean arterial pressure was decreased and heart rate increased both 12 h and 5 days after induction of ACF, but did not differ from shams at 4, 8, and 15 weeks after ACF (Table 1) . Left ventricular end-systolic dimension (LVESD) did not differ from shams at 12 h and 2 and 5 days after ACF. However, at 4 weeks after ACF, LVESD increased by 40% and remained elevated in 8-and 15-week post-ACF rats despite the fact that left ventricular end-systolic (LVES) pressure did not differ from sham (Figs. 3A and 3B ). Left ventricular fractional shortening and velocity of circumferential shortening (VCF r ) were not different from sham values until 15 weeks after ACF, when there was a decrease in VCF r concomitant with an increase in LVES stress (Figs. 3C to 3E ). This decrease in VCF r occurred in the face of normal cardiomyocyte fractional shortening and velocity of shortening ( Table 2) . Indexes of diastolic function in ACF. Left ventricular end-diastolic (LVED) pressure and LVED wall stress (Figs. 4A and 4B) were increased at 2 days and remained elevated throughout the time course, whereas lung wet weight (Fig.  4C ) was increased at 4 to 15 weeks and right ventricular weight (Fig. 4E) was increased from 5 days after ACF onward. Isolated cardiomyocyte relaxation velocity and time to 50% relaxation did not differ in ACF and age-matched shams across all time points, except at 5 days after ACF (Table 2) , whereas LV Ϫ rate of left ventricular pressure decline (dP/dt max ) in ACF did not differ from shams at all time points (Table 1) . 814 Ryan
Hoe 140 and LV remodeling and function in 2-day ACF rats. Hoe 140 prevented the decrease in LV interstitial collagen (Fig. 5A ) and the increase in LVEDD and LVEDD/wall thickness at 2 days after ACF (Table 3) . There was an increase in LVES pressure in both sham ϩ Hoe 140 and ACF ϩ Hoe 140 rats (Table 3) ; however, LVES wall stress did not differ among all groups (data not shown). Left ventricular fractional shortening was increased in sham ϩ Hoe 140 and ACF ϩ Hoe 140 despite an increased left ventricular end-systolic pressure compared with untreated sham and ACF cases (Table 3) . Left ventricular weight/body weight did not increase in either ACF group; total heart weight/body weight increased in ACF versus age-matched shams. In contrast, total heart weight/body weight did not increase in ACF ϩ Hoe 140 versus sham ϩ Hoe 140 and sham rats (Table 3) . At Tables  1 and 2 except: 4-week sham LVEDD, LVEDD/wall thickness, LVED wall thickness (n ϭ 9); 4-week ACF echocardiographic parameters and LV wet weight (n ϭ 9); 8-week sham echocardiographic parameters and LV wet weight (n ϭ 8); 15-week sham LV wet weight (n ϭ 12); and 15-week ACF LV wet weight (n ϭ 9). *p Ͻ 0.008 (ϭ 0.05/6) for sham versus ACF at each time of the 6 time points except for isolated cardiomyocyte length, where p Ͻ 0.01 (ϭ 0.05/5) for each of the 5 time points. Analyses were based on ranks of all the variables in this figure. 21 Left Ventricular Remodeling in Volume Overload increased, whereas TIMP-1 and -4 protein levels were not altered. Hoe 140 prevented the increase in MMP-13 but had no effect on TIMP-1 and -4 levels (Figs. 5B to 5D ).
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To assess whether the effects of Hoe 140 were through a direct mechanism on the heart or an indirect mechanism through increased blood pressure, we infused angiotensin II and achieved a similar increase in MAP as seen with Hoe 140 infusion (Table 4 ). In comparison with ACF alone, angiotensin II partially prevented the decrease in collagen and the increase in LVEDD/wall thickness. However, there was an increase in cardiac hypertrophy in ACF ϩ angiotensin II when compared with the ACF ϩ Hoe 140 (Table 4) . Effect of ramipril on LV remodeling and function in 4-week ACF rats. Ramipril decreased LVES pressure and heart weight/body weight in 4-week post-ACF rats. However, the decrease in LVES pressure was not accompanied by an improvement in fractional shortening, LV dilation, and LVEDD/wall thickness (Table 5) . Ramipril was associated with a further decrease in LV interstitial collagen compared with untreated ACF (Fig. 6 ).
Discussion
The current study provides new insights into the mechanism of eccentric remodeling in response to the volume overload of ACF by combining LV chamber, cardiomyocyte, and interstitial collagen analyses. First, the critical, very early event (12 h to 2 days) in LV remodeling is BK-mediated dissolution of the collagen matrix, and not elongation of the cardiomyocyte. Second, further adverse LV remodeling and LV dysfunction are seen at the 4-week stage of volume overload in the presence of normal cardiomyocyte shape and function. Third, treatment with ACE inhibitor in the first 4 weeks after ACF does not attenuate LV remodeling or improve function and further decreases collagen relative to ACF alone. These findings explain why ACE inhibitors, which increase antifibrotic BK, are ineffective in attenuating LV remodeling in a pure volume overload. BK-mediated collagen dissolution exacerbates acute LV remodeling. Important sequential changes in LV chamber and cardiomyocyte remodeling with ACF are shown in Figure 1 . Within 2 days, there is an increase in LVEDD and LVEDD/wall thickness with no change in cardiomyocyte length. At the same time, there is a marked decrease in interstitial collagen, showing that cardiomyocyte elongation is not the earliest step in LV eccentric remodeling in response to volume overload. This rapid decrease in interstitial collagen is likely to be multifactorial. Simple stretch of cardiac fibroblasts in vitro increases collagenase activity (10) and membrane type 1-MMP expression (11) . In addition, we and others have found an increase in mast cells and BK in this early phase of ACF (4, 12) . Mast cell secretory products such as trypsin, chymase, stromelysin (MMP-3), and cytokines, such as tumor necrosis factor-␣, are potent in vitro activators of MMPs (13) (14) (15) (16) . Inhibition of ACE in ACF rats significantly increased interstitial fluid BK but did not attenuate increases in mast cell density, which was blocked by the addition of BK 2 R blockade, supporting the role of BK as an inflammatory mediator (4) .
In addition to its effects on inflammatory cell recruitment, BK decreases collagen I and III mRNA production in cardiac fibroblasts (5), modulates MMP activation through the plasminogen activator system (17), and increases MMP-2 (6) and MMP-9 (7) expression. Two 
days after the induction of ACF, MMP-13 levels are increased in the absence of changes in TIMP-1 and -4 levels ( Fig. 5 ) and collagen I and III expression (data not shown), suggesting that the decrease in interstitial collagen is caused by increased degradation, but not decreased synthesis. This acute loss of collagen in ACF stands in stark contrast to a marked increase in collagen synthesis that has been reported after 2 days of acute pressure overload in the rat (18) . Thus, an acute inflammatory response [increased BK and mast cell density (4)] coupled with a stretch stimulus, which occurs in the absence of pressure overload, may induce a rapid loss of the collagen matrix. Blockade of BK 2 R prevents an increase in MMP-13 and a decrease of interstitial collagen, and normalizes LVEDD/ wall thickness at 2 days of ACF stress. Further, LVES pressure increases as LVESD trends down 25% vs. untreated ACF rats ( Table 3 ), suggesting that BK 2 R blockade improves LV function. This functional improvement could be a consequence of more efficient transmission of forces Table 1 except: 4-week sham LVESD, LV fractional shortening, and LV VCF r (n ϭ 9); 8-week sham LVESD, LV fractional shortening, and LV VCF r (n ϭ 8). *p Ͻ 0.008 (ϭ 0.05/6) sham versus ACF at each of the 6 time points. Analyses for left ventricular end-systolic pressure (LVESP), LVESD, and LVVCFr were based on their ranks, whereas analyses for LV fractional shortening and LVES were based on their natural logarithms.
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between adjacent myocytes and myofibers because of a preservation of the matrix. Interestingly, antagonism of BK 2 R in ACF animals is associated with a decrease in cardiac hypertrophy despite the increase in MAP. To test whether the local cardiac effects of BK 2 R blockade are important, or whether functional and remodeling improvements during ACF are attributable to the increase in blood pressure caused by BK 2 R blockade, we examined the effect of a hypertensive challenge that was similar in magnitude to that seen with Hoe 140 treatment. Using angiotensin II infusion, we achieved an increase in blood pressure at 2 days after ACF equivalent to that seen with Hoe 140 treatment. Similar to Hoe 140, angiotensin II increased collagen matrix and normalized LVEDD/wall thickness compared with ACF alone; unlike Hoe 140, it also increased cardiac hypertrophy. Because BK is upregulated acutely in the LV during ACF, it is tempting to speculate that its blockade in the heart prevents the loss of collagen through a direct mechanism rather than through an indirect effect on blood pressure. At 5 days after ACF, the collagen volume percent returns to normal; however, this rebound is abnormal because there are fewer collagen fibers and these fibers are thicker than normal (Fig. 2) . This rebound in collagen occurs in the absence of an increase in MAP, and may also be a response to a local increase in cardiac interstitial angiotensin II (4). The change in collagen structure could be a temporary adaptive response because it is associated with a cessation of further LV dilation at 5 days. However, at 4 weeks after ACF there is a subsequent decrease in extracellular matrix and a marked increase in LVEDD/wall thickness. Adverse LV remodeling and dysfunction in chronic volume overload. Another important finding of this study is that LV systolic and diastolic dysfunction (4 to 15 weeks) is not related to cardiomyocyte dysfunction. There is evidence of LV systolic dysfunction as early as the 4-week stage of ACF (Fig. 3) , manifested by an increase in LVESD, whereas LV fractional shortening does not increase despite an increase in preload and normal LVES wall stress. At 4 weeks after ACF, LVESD is increased in the presence of normal LVES pressure, resulting in a significant increase in LVES wall stress at 15-week ACF. It is also important to note that there is no incremental increase in LV hypertrophy 4 weeks after induction of ACF, despite an increase in LVES wall stress at 15 weeks. In addition, ACF LV wall thickness is decreased and cardiomyocytes are elongated at 15 weeks, accentuating adverse eccentric LV remodeling and contributing to a decrease in LV VCF r , all in the face of normal cardiomyocyte function. At a similar ACF time point, Wang et al. (19) found enhanced LV ␤ 1 -receptor density and increased basal activity. Thus, the disparity between isolated myocyte function in vitro and LV chamber function in vivo could be caused by loss of collagen structural support. Tables 1 and 3 . Left ventricular end-diastolic pressure and wall stress are elevated as early as 2 days after ACF and throughout the entire time course (Fig. 4) . Lung wet-weight is also increased, indicative of decreased LV compliance despite the decrease in interstitial collagen and normal indexes of cardiomyocyte relaxation throughout 15 weeks after ACF (Table 2 ). Previous studies in ACF rats at 6 weeks showed an increase in collagen cross-linkage and no change in collagen content, resulting in a stiffer LV chamber (20) . Thus, a simple assessment of collagen content without regard to collagen cross-linking or subtype distribution, especially in volume overload, could obscure changes in chamber compliance. Our results suggest that the progressive LV remodeling and systolic dysfunction, which is disproportionate to cardiomyocyte remodeling, results from dissolution of the collagen matrix. Chronic ACE inhibition does not attenuate LV remodeling in volume overload. We found that ACE inhibition increased collagen loss at 4 weeks after ACF (Fig. 6 ) and did not attenuate adverse LV chamber remodeling as summarized in Table 5 . With ACF ϩ ACE inhibitor treatment, LVEDD/wall thickness and LVED wall stress remained elevated and LVESD increased relative to ACF-untreated rats, even though there was a decrease in LVES pressure and cardiac hypertrophy. The failure to improve LV remodeling and function may be caused by an ACE inhibitor-induced loss of supporting collagen structure that results in further cardiomyocyte elongation. Our BK 2 R blockade studies suggest that ACE inhibitorinduced increase in BK contributes to the acute adverse remodeling seen in volume overload after ACF. However, we do not show the role of long-term BK 2 R activation in the heart on the volume overloaded LV, and therefore, the mechanism of the long-term deleterious effects of chronic ACE inhibition remains uncertain. We have shown a similar loss of collagen and MMP activity in early and late phases of mitral regurgitation in the dog (21) . Indeed, ACE inhibitor or angiotensin II receptor blockade failed to attenuate LV remodeling in dogs with mitral regurgitation (8, 22) , and we have shown that such therapy results in further cardiomyocyte elongation (8) . Finally, ACE inhibitor or angiotensin II receptor blockade have not been shown to be beneficial in patients with pure volume overload due to valvular regurgitation (2) . Summary. Here we show that an increase in LVEDD/ wall thickness, previously thought to be caused by myocyte elongation, may have less to do with myocyte length and more to do with matrix changes that affect the collagen scaffolding connecting individual myocytes and collections of myocytes that comprise the laminar structure of the heart (23). We also show that the BK- Figure 6 Volume Percent of Collagen in Ramipril-Treated Sham and ACF Rats
